RP

Regeneron Pharmaceuticals, Inc.

Q2 FY26Biotechnology

Regeneron Pharmaceuticals, Inc. Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹622

Market cap₹65.2K Cr

P/E15.5

Updated29 May 2026

Read4 min read

What the Q2 FY26 call signalled

2 of 3 strong

RevenueGood growth

MarginMargins slightly down

CapexCapex planned

The short version

- DUPIXENT sales expected to exceed $30 billion globally, driven by growth across all indications and geographies. - Continued strong uptake of EYLEA HD with 52% year-over-year growth in U.S. - Regeneron delivered double-digit growth in Q1 2026 with total revenues up 19% YoY and non-GAAP EPS increasing 15%.

From Regeneron Pharmaceuticals, Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Good growth

DUPIXENT sales expected to exceed $30 billion globally, driven by growth across all indications and geographies.
Continued strong uptake of EYLEA HD with 52% year-over-year growth in U.S. net sales; anticipated sequential unit demand growth consistent with Q1.
EYLEA sales declining due to conversion to EYLEA HD, competition, and affordability; expected mid- to high-teens decline in Q2.
Libtayo sales growing 54% globally, with continued uptake in skin cancers and lung cancer; early growth from new adjuvant CSCC indication.
Pipeline advancements (e.g., cemdisiran, olatorepatide, garetosmab) anticipated to support long-term revenue expansion.

2 more points from Regeneron Pharmaceuticals, Inc.'s call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

Regeneron delivered double-digit growth in Q1 2026 with total revenues up 19% YoY and non-GAAP EPS increasing 15%.
The company anticipates sustained growth in key products like DUPIXENT (31% YoY growth) and Libtayo (54% YoY growth).
Sanofi collaboration revenue is expected to increase starting Q3 2026 as the Sanofi development balance will be fully repaid by end of Q2.
GAAP gross margin guidance was updated to 77%-78% for 2026 due to temporary manufacturing interruptions, with margins expected to improve by end of Q2.
Ongoing investments in R&D and multiple late-stage pipeline programs suggest continued prospects for revenue and profit expansion.

2 more points from Regeneron Pharmaceuticals, Inc.'s call on margins

Pro opens every point from 15K+ earnings calls

See what Regeneron Pharmaceuticals, Inc. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned

Regeneron continues aggressive investment in R&D, supporting late-stage and early-stage pipeline programs across multiple therapeutic areas including hematology/oncology, complement-mediated diseases, and immunology.
The company has authorized a new $3 billion share repurchase program, reflecting confidence in its financial position and business outlook.
Strategic collaborations include:
Partnership with Telix for co-development and commercialization of next-generation radiopharmaceutical therapies.
Collaboration with TriNetX to leverage real-world clinical data linked to genomic and proteomic information, accelerating drug discovery.
Capital allocation balances internal investment in science and pipeline with capital returns to shareholders and business development.

2 more points from Regeneron Pharmaceuticals, Inc.'s call on capex

Pro opens every point from 15K+ earnings calls

Fundraising & Capital Structure

There is no mention of any new fundraising through debt or equity in the provided document.
The company ended Q1 2026 with $15.8 billion in cash and marketable securities less debt, indicating a strong cash position.
The Board of Directors authorized a new $3 billion share repurchase program, reflecting confidence in the business and financial position.

2 more points from Regeneron Pharmaceuticals, Inc.'s call on fundraising

Pro opens every point from 15K+ earnings calls

See what Regeneron Pharmaceuticals, Inc. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The document does not provide specific details on current, expected orderbook, or pending orders for Regeneron. However, key points relevant to demand and sales outlook include: - Strong ongoing demand for key products such as DUPIXENT, EYLEA HD, and Libtayo, with continued growth in multiple indications and geographies. - Physician demand for EYLEA HD increased sequentially by 10% in Q1 2026. - Anticipated approval for EYLEA HD prefilled syringe expected to drive uptake. - Expected sequential unit demand growth for EYLEA HD in Q2 2026 consistent with Q1. - Decline in EYLEA sales due to conversion to EYLEA HD, competition, and affordability; mid- to high-teens expected decline in Q2. - Libtayo sales showed strong growth driven by advances in skin cancer indications.

2 more points from Regeneron Pharmaceuticals, Inc.'s call on order book

Pro opens every point from 15K+ earnings calls

Others in Biotechnology this season

Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a

Compare:vs AbbVie Inc.vs Vertex Pharmaceuticals Incorporated vs argenx SE

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Regeneron Pharmaceuticals, Inc. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Regeneron Pharmaceuticals, Inc. Q2 FY26 results?

- DUPIXENT sales expected to exceed $30 billion globally, driven by growth across all indications and geographies. - Continued strong uptake of EYLEA HD with 52% year-over-year growth in U.S. - Regeneron delivered double-digit growth in Q1 2026 with total revenues up 19% YoY and non-GAAP EPS increasing 15%.

What is Regeneron Pharmaceuticals, Inc. share price analysis?

Regeneron Pharmaceuticals, Inc. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 15.5 with a market cap of $65,160. Investors should review the full earnings analysis for detailed insights.

Is Regeneron Pharmaceuticals, Inc. planning capital expenditure?

- Regeneron continues aggressive investment in R&D, supporting late-stage and early-stage pipeline programs across multiple therapeutic areas including hematology/oncology, complement-mediated diseases, and immunology.

Keep Regeneron Pharmaceuticals, Inc. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.